Abbvie S | search
Click here to view Abbvie S news from 60+ newspapers.
Bookmark or Share- AbbVie Completes Acquisition of ImmunoGen - Feb 12, 2024February 12, 2024. AbbVie Completes Acquisition of ImmunoGen. Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio.
- Pharmaceutical Research & Development | AbbVieAbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives
- AbbVie to Acquire Cerevel Therapeutics in Transformative ...AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline. Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain.
- Products | AbbVieProducts | AbbVie. Patients. Products. View names and safety data sheets for our products. The product information provided below is intended for residents of the U.S. only. Patient Assistance. myAbbVie Assist. Learn More. products. 60. +. conditions treated across all stages of life. Company. ~50. k.
- AbbVie - WikipediaAbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. [2] .
More
